{
    "clinical_study": {
        "@rank": "21516", 
        "arm_group": {
            "arm_group_label": "FFP+HDMP+Rituximab", 
            "arm_group_type": "Experimental", 
            "description": "Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP),\n      high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic\n      leukemia."
        }, 
        "brief_title": "Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Chronic lymphocytic leukemia remains incurable and particularly in ultra-high risk subgroup,\n      and the prognosis of these patients is still dismal.\n\n      This is a phase III, multicenter perspective clinical trial of combination of fresh frozen\n      plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic\n      lymphocytic leukemiaThe. The main purpose of this study is to investigate efficacy and\n      safety of this combinated regimen in subgroup of CLL patients.\n\n      All the enrolled patients will be followed during and after the treatment period up to one\n      year. Interim and final evaluation will be done after each cycle of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 18-80 years old.\n\n          2. Diagnosis of chronic lymphocytic leukemia.\n\n          3. Active disease meeting at least one of the International Workshop on Chronic\n             Lymphocytic Leukemia 2008 criteria for requiring treatment.\n\n          4. Ultra-high risk CLL(Meets at least one of the following criteria) (1)ultra high-risk\n             genetics (17p deletion and/or TP53 mutation) (2)short PFS(<24 months)after intense\n             immunochemotherapy treatment(i.e. FCR, FR, PCR, BR etc) (3)fludarabine-refractory\n\n          5. Understand and voluntarily sign an informed consent form, able to adhere to the study\n             visit schedule and other protocol requirements\n\n        Exclusion Criteria:\n\n          1. Severe allergic constitution or asthma.\n\n          2. Recent myocardial infarction or hypotension.\n\n          3. ECOG performance status of \u2264 2 at study entry.\n\n          4. Active hepatitis B(DNA >1\u00d7103/ml)\n\n          5. Severe and uncontrolled diabetes mellitus.\n\n          6. Severe and uncontrolled hypertension(BP> 150/90 mmHg after treatment).\n\n          7. Active and uncontrolled systematic infection which need treatment of antibiotics.\n\n          8. Clinical symptoms of dysfunction of central nervous system.\n\n          9. Unstable and severe gastrorrhagia and peptic ulcer.\n\n         10. Major surgery within three weeks.\n\n         11. Any potential drug abuse, medical, psychological or social conditions which may\n             disturb this investigation and assessment.\n\n         12. In any conditions which investigator considered ineligible for this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670812", 
            "org_study_id": "JSPH-CLL-001"
        }, 
        "intervention": {
            "arm_group_label": "FFP+HDMP+Rituximab", 
            "description": "This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5", 
            "intervention_name": "FFP+HDMP+Rituximab", 
            "intervention_type": "Drug", 
            "other_name": [
                "fresh frozen plasma", 
                "methylprednisolone", 
                "rituximab"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chronic lymphocytic leukemia", 
            "ultra-high risk", 
            "fresh frozen plasma", 
            "methylprednisolone", 
            "rituximab"
        ], 
        "lastchanged_date": "August 19, 2012", 
        "location": [
            {
                "contact": {
                    "email": "Zmsun_vip@163.com", 
                    "last_name": "Zimin Sun, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "state": "Anhui"
                    }, 
                    "name": "The First affiliated Hospital of AnHui Medical Universtiy"
                }, 
                "investigator": {
                    "last_name": "Zimin Sun, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zhougene@medmail.com.cn", 
                    "last_name": "Jianfeng Zhou, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "TongJi Hospital"
                }, 
                "investigator": {
                    "last_name": "Jianfeng Zhou, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "XiangShan Cao, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "ChangZhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "213003"
                    }, 
                    "name": "ChangZhou First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "XiangShan Cao, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Min Zhou, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "ChangZhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "213011"
                    }, 
                    "name": "ChangZhou No.2 People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Min Zhou, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liang Yu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "HuaiAn", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223300"
                    }, 
                    "name": "HuaiAn First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Liang Yu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "LEI FAN, Dr.", 
                    "phone": "86 25 6813 6034"
                }, 
                "facility": {
                    "address": {
                        "city": "NanJing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "JiangSu Province Hospital"
                }, 
                "investigator": {
                    "last_name": "WEI XU, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "YanLi Xu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "NanJing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210006"
                    }, 
                    "name": "NanJing First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YanLi Xu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xuemei Sun, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "JiangSu Province Hospital of TCM"
                }, 
                "investigator": {
                    "last_name": "Xuemei Sun, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yun Zhuang, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "WuXi", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "214023"
                    }, 
                    "name": "WuXi People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YunFeng Shen, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yan Zhu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "ZhenJiang", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "212002"
                    }, 
                    "name": "ZhenJiang First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Yan Zhu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xin Wang, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong"
                    }, 
                    "name": "Shandong Provincial Hospital"
                }, 
                "investigator": {
                    "last_name": "Xin Wang, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Aibin Liang, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "TongJi Medical University affiliated TongJi Hospital"
                }, 
                "investigator": {
                    "last_name": "Aibin Liang, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ting Liu, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Chendu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }, 
                    "name": "West China School of Medicine, West China Hospital, Sichuan University"
                }, 
                "investigator": {
                    "last_name": "Ting Liu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drqiu99@medmail.com.cn", 
                    "last_name": "Lugui Qiu, M.D., Ph.D.", 
                    "phone": "+86 22 2390 9999"
                }, 
                "facility": {
                    "address": {
                        "city": "TianJin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "Institute of Hematology & Blood Diseases Hospital"
                }, 
                "investigator": {
                    "last_name": "Lugui Qiu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "fanlei_fl@yahoo.com.cn", 
            "last_name": "LEI FAN, M.D., Ph.D.", 
            "phone": "+86 25 6813 6034"
        }, 
        "overall_official": {
            "affiliation": "Jiangsu Province Hospital", 
            "last_name": "Wei Xu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "overall response rate after treated by FFP+HDMP+Rituximab regimen", 
            "measure": "overall response rate", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "reference": [
            {
                "PMID": "20635386", 
                "citation": "Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ, Wang DM, Wu YJ, Qiao C, Li JY. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer. 2011 May 1;128(9):2192-201. doi: 10.1002/ijc.25560."
            }, 
            {
                "PMID": "20627536", 
                "citation": "Xu W, Miao KR, Hong M, Zhu DX, Fang C, Dong HJ, Wang DM, Cao X, Li JY. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. Eur J Cancer. 2010 Aug;46(12):2145-9. Epub 2010 Jun 4."
            }, 
            {
                "PMID": "18310545", 
                "citation": "Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008 Mar;93(3):475-6."
            }, 
            {
                "PMID": "19758239", 
                "citation": "Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci. 2009 Sep;1173:865-73. Erratum in: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami]."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670812"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jiangsu Province Hospital", 
            "investigator_full_name": "WEI XU", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "progression free survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients.", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "overall survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "Number of Participants with Adverse Events, and evaluated standard is according to common terminology criteria adverse events(CTCAE) version 4.0", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after last dose of treatment"
            }
        ], 
        "source": "Jiangsu Province Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Province Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}